AM Eastern time on Thursday, February 12, 2026 Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. –) – Medexus Pharmaceuticals ...

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

NHS England » Provisional publication of Never Events reported as occurring between April 2025 and December 2025 ...

The middle meningeal artery (MMA) has emerged as a potential therapeutic target for severe, treatment-resistant headache syndromes. Growing evidence suggests that the MMA and its dural branches are ...